Publication | Closed Access

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

First-line Atezolizumab MonotherapyMedicinePharmacologyClinical TrialsImmune Checkpoint InhibitorSingle-agent ChemotherapyPharmacotherapyCancer TreatmentOncologyLung CancerPhase 3